The present study is relevant to the ongoing exploration of NGAL as a biomarker for gastrointestinal disease, in particular the two forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD). Here, LCN2 is linked to inflammatory bowel disease.